Last reviewed · How we verify
Dutasteride Capsules
Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT) and reducing DHT levels in the prostate.
Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT) and reducing DHT levels in the prostate. Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms.
At a glance
| Generic name | Dutasteride Capsules |
|---|---|
| Also known as | Avodart |
| Sponsor | UConn Health |
| Drug class | 5-alpha reductase inhibitor |
| Target | 5-alpha reductase (type 1 and type 2) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting 5-alpha reductase, dutasteride prevents the formation of DHT, the primary androgen responsible for prostate growth. This leads to shrinkage of an enlarged prostate and reduction in urinary symptoms associated with benign prostatic hyperplasia. The dual inhibition of both enzyme isoforms makes it more potent than selective type 1 inhibitors.
Approved indications
- Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms
Common side effects
- Erectile dysfunction
- Decreased libido
- Ejaculation disorder
- Gynecomastia
- Breast tenderness
Key clinical trials
- A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects (PHASE1)
- Phase II Dutasteride in Combination With CAB vs CAB in SDC (PHASE2)
- Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy (PHASE2, PHASE3)
- A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia (PHASE3)
- The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms (NA)
- Study of PCUR-101 in Combination With ADT in Patients With mCRPC (PHASE1)
- Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia (PHASE3)
- Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |